FR15C0081I2 - Expression optimisee de hpv 58 l1 dans de la levure - Google Patents

Expression optimisee de hpv 58 l1 dans de la levure

Info

Publication number
FR15C0081I2
FR15C0081I2 FR15C0081C FR15C0081C FR15C0081I2 FR 15C0081 I2 FR15C0081 I2 FR 15C0081I2 FR 15C0081 C FR15C0081 C FR 15C0081C FR 15C0081 C FR15C0081 C FR 15C0081C FR 15C0081 I2 FR15C0081 I2 FR 15C0081I2
Authority
FR
France
Prior art keywords
hpv
yeast
optimized expression
optimized
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR15C0081C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of FR15C0081I1 publication Critical patent/FR15C0081I1/fr
Application granted granted Critical
Publication of FR15C0081I2 publication Critical patent/FR15C0081I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR15C0081C 2003-11-12 2015-12-04 Expression optimisee de hpv 58 l1 dans de la levure Active FR15C0081I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51921103P 2003-11-12 2003-11-12
PCT/US2004/037372 WO2005047315A2 (fr) 2003-11-12 2004-11-10 Expression optimisee de hpv 58 l1 dans de la levure

Publications (2)

Publication Number Publication Date
FR15C0081I1 FR15C0081I1 (fr) 2016-08-01
FR15C0081I2 true FR15C0081I2 (fr) 2016-11-25

Family

ID=34590374

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0081C Active FR15C0081I2 (fr) 2003-11-12 2015-12-04 Expression optimisee de hpv 58 l1 dans de la levure

Country Status (32)

Country Link
US (2) US7498036B2 (fr)
EP (1) EP1687329B8 (fr)
JP (2) JP4912885B2 (fr)
KR (1) KR101170654B1 (fr)
CN (1) CN1942583B (fr)
AR (1) AR046835A1 (fr)
AT (1) ATE452977T1 (fr)
AU (1) AU2004290032B2 (fr)
BE (1) BE2015C070I2 (fr)
BR (1) BRPI0416393B1 (fr)
CA (1) CA2543928C (fr)
CY (2) CY1113875T1 (fr)
DE (1) DE602004024821D1 (fr)
DK (1) DK1687329T3 (fr)
ES (1) ES2340287T3 (fr)
FR (1) FR15C0081I2 (fr)
HU (1) HUS1500064I1 (fr)
IL (1) IL175353A (fr)
IS (1) IS2741B (fr)
LT (1) LTC1687329I2 (fr)
LU (1) LU92901I2 (fr)
MY (1) MY139500A (fr)
NL (1) NL300775I2 (fr)
NO (2) NO340633B1 (fr)
NZ (1) NZ546697A (fr)
PL (1) PL1687329T3 (fr)
PT (1) PT1687329E (fr)
RU (1) RU2370538C2 (fr)
SI (1) SI1687329T1 (fr)
TW (1) TWI332988B (fr)
WO (1) WO2005047315A2 (fr)
ZA (1) ZA200603106B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US8206950B2 (en) * 2003-06-09 2012-06-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine and method of making them
KR101203403B1 (ko) * 2004-03-24 2012-11-21 머크 샤프 앤드 돔 코포레이션 효모에서 ｈｐｖ 52 ｌ1의 최적화된 발현
US20070243587A1 (en) * 2006-04-14 2007-10-18 Healthbanks Biotech Co., Ltd. Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus
CN101148661B (zh) * 2006-09-18 2013-01-02 中国医学科学院基础医学研究所 人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途
US7709010B2 (en) * 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
BRPI0815818A2 (pt) 2007-04-29 2016-08-02 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 truncada do papiloma vírus humano tipo 18
WO2008134934A1 (fr) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Protéine l1 tronquée du papillomavirus 16 humain
BRPI0810951B8 (pt) * 2007-05-29 2021-05-25 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
CN101113417B (zh) * 2007-06-22 2011-04-27 山东大学 Hpv基因酵母体外翻译系统的建立
CN101200696B (zh) * 2007-11-14 2011-07-20 山东大学 人乳头瘤病毒的酵母增殖模型及建立方法与应用
CN101835797A (zh) 2007-11-23 2010-09-15 上海泽润生物科技有限公司 人乳头状瘤病毒主要衣壳蛋白l1基因及其用途
KR20090073987A (ko) * 2007-12-31 2009-07-03 정운원 인간유두종바이러스 유전자형 검사를 위한 프라이머, 프로브 및 이를 포함하는 ｄｎａ칩, 이의 검사 방법 및 검사 키트
JP5726727B2 (ja) * 2008-05-26 2015-06-03 カディラ・ヘルスケア・リミテッド 麻疹−ヒトパピローマ混合ワクチン
US9335868B2 (en) * 2008-07-31 2016-05-10 Apple Inc. Capacitive sensor behind black mask
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
CN101857870B (zh) * 2010-06-12 2012-09-05 上海泽润生物科技有限公司 Hpv58 l1基因及载体、菌株和表达方法
US9382296B2 (en) 2010-07-16 2016-07-05 Xiamen University Truncated L1 protein of human papillomavirus type 58
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
EP2722389B1 (fr) * 2011-06-15 2018-03-07 Hong Jin Kim Procédé d'augmentation du rendement de production d'une protéine l1 du papillomavirus humain
CN108624614A (zh) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
AU2013272283B2 (en) 2012-06-07 2018-02-15 The Children's Hospital Of Philadelphia Controlled gene expression methods
CN103992395B (zh) * 2013-02-18 2018-07-27 北京康乐卫士生物技术股份有限公司 重组hpv-58型l1的vlp疫苗及其制备方法
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104164373B (zh) * 2013-05-17 2019-04-02 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv68l1蛋白的方法
CN104164374B (zh) * 2013-05-17 2019-10-22 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
CA2927434C (fr) 2013-10-16 2022-07-19 Merck Sharp & Dohme Corp. Procede d'obtention de formulations de vaccin sechees thermostables
CA2958222A1 (fr) * 2014-09-11 2016-03-17 Cadila Healthcare Limited Antigenes superieurs du papillomavirus presentant des proprietes immunologiques superieures et vaccin les contenant
CN106148359A (zh) * 2015-03-30 2016-11-23 上海泽润生物科技有限公司 重组人乳头瘤病毒33亚型蛋白表达
CN104878022A (zh) * 2015-04-27 2015-09-02 段青姣 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
CN106831961B (zh) * 2015-12-04 2019-11-05 厦门大学 一种人乳头瘤病毒58型l1蛋白的突变体
IL295234A (en) 2020-02-14 2022-10-01 Merck Sharp & Dohme Llc HPV vaccine
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) * 2021-06-07 2023-03-31 郑州大学 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
AR126708A1 (es) 2021-08-06 2023-11-08 Merck Sharp & Dohme Llc Vacuna para el vph
WO2023023152A1 (fr) 2021-08-19 2023-02-23 Merck Sharp & Dohme Llc Nanoparticule lipidique thermostable et ses méthodes d'utilisation
CN117054647A (zh) * 2023-07-17 2023-11-14 广东省一鼎生物技术有限公司 一种检测HPV IgG抗体试剂盒及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
PL335050A1 (en) 1997-02-07 2000-03-27 Merck & Co Inc Synthetic genes gag hiv
JP4434479B2 (ja) 1997-07-09 2010-03-17 ザ・ユニバーシティ・オブ・クイーンズランド 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
ES2275350T3 (es) 1998-08-14 2007-06-01 MERCK & CO., INC. Sistema de administracion de proteinas usando particulas de tipo virus de papilomavirus humano.
EA200100236A1 (ru) * 1998-08-14 2001-08-27 Мерк Энд Ко., Инк. Способ очистки вирусных частиц, подобных вирусу папилломы человека
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
WO2001014416A2 (fr) * 1999-08-25 2001-03-01 Merck & Co., Inc. Genes synthetiques humains du virus de papillome
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
PL365385A1 (en) 2000-07-21 2005-01-10 Glaxo Group Limited Codon-optimized papilloma virus sequences
AU2003217413A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
ES2381964T3 (es) * 2003-03-24 2012-06-04 Merck Sharp & Dohme Corp. Expresión optimizada de L1 de VPH 31 en levadura
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Also Published As

Publication number Publication date
US7976848B2 (en) 2011-07-12
BE2015C070I2 (fr) 2023-12-18
LTC1687329I2 (lt) 2017-05-10
IS2741B (is) 2011-06-15
FR15C0081I1 (fr) 2016-08-01
MY139500A (en) 2009-10-30
SI1687329T1 (sl) 2010-03-31
CN1942583B (zh) 2010-10-27
US7498036B2 (en) 2009-03-03
JP2012095652A (ja) 2012-05-24
CA2543928A1 (fr) 2005-05-26
AU2004290032A1 (en) 2005-05-26
CN1942583A (zh) 2007-04-04
US20100272749A1 (en) 2010-10-28
NL300775I1 (fr) 2015-12-29
NL300775I2 (fr) 2015-12-29
JP5616879B2 (ja) 2014-10-29
NO20062674L (no) 2006-06-09
JP4912885B2 (ja) 2012-04-11
CY2015051I1 (el) 2016-06-22
LU92901I2 (fr) 2016-03-08
ZA200603106B (en) 2007-09-26
PT1687329E (pt) 2010-02-26
NZ546697A (en) 2009-05-31
KR20060122852A (ko) 2006-11-30
EP1687329B1 (fr) 2009-12-23
CY1113875T1 (el) 2016-06-22
TW200519203A (en) 2005-06-16
BRPI0416393B1 (pt) 2021-06-29
KR101170654B1 (ko) 2012-08-03
AR046835A1 (es) 2005-12-28
IS8425A (is) 2006-04-21
NO2017058I1 (no) 2017-11-10
EP1687329A2 (fr) 2006-08-09
WO2005047315A2 (fr) 2005-05-26
JP2008500019A (ja) 2008-01-10
RU2370538C2 (ru) 2009-10-20
EP1687329B8 (fr) 2010-03-17
WO2005047315A3 (fr) 2006-09-28
PL1687329T3 (pl) 2010-06-30
US20070036824A1 (en) 2007-02-15
ES2340287T3 (es) 2010-06-01
DK1687329T3 (da) 2010-04-12
HUS1500064I1 (hu) 2016-02-29
CA2543928C (fr) 2011-04-05
BRPI0416393A (pt) 2007-04-03
IL175353A (en) 2010-11-30
AU2004290032B2 (en) 2009-02-05
IL175353A0 (en) 2006-09-05
TWI332988B (en) 2010-11-11
RU2006120402A (ru) 2007-12-27
CY2015051I2 (el) 2016-06-22
NO340633B1 (no) 2017-05-15
DE602004024821D1 (de) 2010-02-04
ATE452977T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
FR15C0081I2 (fr) Expression optimisee de hpv 58 l1 dans de la levure
FR15C0083I2 (fr) Expression optimisee de hpv45 l1 dans la levure
FR15C0085I2 (fr) Expression optimisee de hpv 52 l1 dans une levure
DE60318819D1 (de) Hitzestabile mutanten von stärkebiosyntheseenzymen
ATE453321T1 (de) Flüssige hefe-zusammensetzungen
FR2842104B1 (fr) Genes impliques dans la canitie precoce
ES1055129Y (es) Secadora-abrillantadora de cubiertos y similares.
ITMI20051170A1 (it) "dispositivo di compressione e procedimento per farlo funzionare"
ITMC20030128A1 (it) Conversione in positivo della spinta negativa tramite
ES1054343Y (es) "matriz de accionamiento manual de pletinas falleba"